Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Triple Negative Breast Neoplasms 163Breast Neoplasms 162Carcinoma, Non-Small-Cell Lung 60Melanoma 44Ovarian Neoplasms 42Colorectal Neoplasms 37Carcinoma, Renal Cell 36Squamous Cell Carcinoma of Head and Neck 33Pancreatic Neoplasms 29Stomach Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 24Neoplasms 24Endometrial Neoplasms 24Lung Neoplasms 19Head and Neck Neoplasms 19Esophageal Neoplasms 18Carcinoma, Transitional Cell 18Carcinoma, Hepatocellular 16Urinary Bladder Neoplasms 14Small Cell Lung Carcinoma 14Prostatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Sarcoma 10Mesothelioma 9Kidney Neoplasms 9Cholangiocarcinoma 9Carcinoma, Ovarian Epithelial 9Carcinoma, Merkel Cell 9Fallopian Tube Neoplasms 8

Interventions

olaparib 4Carboplatin 2talazoparib 1pembrolizumab 1Surveys and Questionnaires 1Paclitaxel 1Genotype 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × pembrolizumab × Breast × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡